Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also ...
Eli Lilly's performance in the biopharmaceutical sector reflects its strong market position, despite facing challenges. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback